By Mario Peshev, DevriX
A deal partner does not lose sleep over lead-routing rules or a Salesforce field that nobody fills in. They lose sleep over a forecast that misses by 30% in the quarter before a refinancing, a pipeline that turns out to be half air during a bolt-on integration, and a management team that cannot tell them why net revenue retention slipped without a two-week fire drill. RevOps, when it works, is the machinery that keeps those three things from happening. When it does not work, it is a line item that consumed budget and produced dashboards.
I have sat on both sides of this. I have watched portfolio companies buy RevOps as a tooling project and I have watched sponsors treat it as a value-creation lever with a number attached. The difference is not the software. The difference is whether anyone connected the work to enterprise value before the check cleared. This piece is my attempt to give a deal partner or operating partner a way to decide what to fund and, harder, how to judge whether it is working.
The question is not “do we have RevOps,” it is “does it move the model”
Most PE-backed B2B companies already have something they call RevOps. A CRM admin, a marketing ops contractor, a spreadsheet that reconciles the two. The presence of the function tells you nothing. The question that matters to a sponsor is narrower: does this function change any input in the LBO model, or is it overhead dressed up as strategy?
The inputs a RevOps function can genuinely touch are limited and they are all financial. It can improve win rate, which shows up as revenue growth without proportional CAC. It can shorten the sales cycle, which pulls cash forward. It can reduce revenue leakage, discounting, churn, renewal slippage, which protects EBITDA. And it can make the forecast reliable, which lowers perceived risk and, at exit, supports the multiple. Everything else RevOps produces is instrumentation in service of those four things.
If a RevOps proposal cannot name which of those four it moves and by roughly how much, it is a request to fund activity. That is the vendor register failure mode: hours, tickets, and dashboards presented as if they were outcomes. A deal partner should treat “we cleaned up the CRM” the same way a CFO treats “we were busy.” Interesting, not decisive.
What the deal partner needs versus what the operating partner needs
These are different readers with different clocks, and RevOps has to answer both.
The deal partner wants the thesis to hold and the exit to be defensible
At the deal level, RevOps is a diligence and de-risking story. The question is whether the commercial engine described in the investment memo is real and repeatable. If the thesis rests on cross-sell into the installed base, the deal partner needs to know the company can actually see who owns which product and what the attach rate is. If the thesis is pricing, they need to know the discounting is measurable and controllable. Most of the commercial due diligence red flags I see in B2B businesses come down to a company that cannot produce clean, segmented revenue data on demand. That is a RevOps deficiency wearing a diligence costume.
The operating partner wants adoption, speed, and a repeatable playbook
The operating partner lives with the company for the hold period. They do not want a beautiful architecture that the sales team ignores. They want the pipeline meeting to be shorter and more honest, the ramp time for a new rep to drop, and the same motion to be portable to the next add-on. This is where the tooling-versus-operator distinction bites hardest, and it is the reason I keep arguing that value creation requires embedded partners, not advisory firms. A deck about ideal state RevOps does not survive contact with a sales floor that has run the same broken process for eight years.
The four numbers that decide whether it is working
I judge a RevOps function on outcomes, not artifacts. Four numbers do most of the work, and each one maps to something the model cares about.
Forecast accuracy against a stated baseline
This is the single most underrated commercial metric in a PE-backed company. A sponsor’s tolerance for missing a covenant test is low, and a forecast that swings 20 to 40 points quarter to quarter is a governance problem before it is a sales problem. Good RevOps produces a forecast the CFO will actually defend to the board. When Bain’s annual Global Private Equity Report notes how much of the industry’s returns now have to come from operating improvement rather than multiple expansion and leverage, forecast reliability is exactly the kind of unglamorous operating discipline that separates a clean hold from a scramble.
Win rate, by segment, not blended
Blended win rate hides everything. A RevOps function earns its budget when it can show win rate by segment, by source, by product, and can tie a change to a specific intervention. This is the ground a fractional CRO fixes: win rate and CAC, not revenue theory. If the number does not move within two or three quarters of a real intervention, either the diagnosis was wrong or the change never reached the reps.
Revenue leakage, measured in currency
Discount creep, silent churn, renewals that slip a quarter, expansion that never gets asked for. Every one of these is EBITDA leaving the building. I wrote a whole B2B portfolio revenue leakage diagnostic because most companies cannot put a dollar figure on it, which means they cannot prioritize fixing it. RevOps that surfaces leakage in currency terms is worth more than RevOps that surfaces it as a chart.
Sales cycle length and its effect on cash
A shorter cycle is not just efficiency. In a leveraged business, pulling cash forward has real value, and a cycle that compresses across the whole team is a repeatable, portable win. This is realized value, not forecast value, and it is one of the cleaner things to prove.
How to read a RevOps proposal like a diligence document
When a portfolio CEO or a vendor brings you a RevOps plan, read it the way you would read a QoE. Ask where the baseline is, what the intervention is, and what the number is supposed to do. If the plan leads with a technology stack, that is the tell. Tools are the last 20% of the decision, not the first.
I apply a short filter:
- What is the baseline? If nobody can tell you today’s win rate by segment or today’s forecast accuracy, the first deliverable is measurement, not transformation. That is fine, but price it as diagnosis.
- Which of the four levers? A plan that claims to move all four at once in the first hundred days is a plan written by someone who has not done it. Pick the one the thesis depends on most.
- Realized, run-rate, or enabled? Be ruthless here. “We built the reporting to see churn” is enabled value. “Churn dropped 3 points and here is the cohort” is realized. Do not let one read as the other in a board deck.
- Who owns the P&L consequence? This is the difference between a consultant and an operator. The distinction between value creation consultants and operators is advice versus P&L accountability, and RevOps that is not accountable to a number is decoration.
McKinsey’s private capital work and BCG’s principal investors research both keep pointing at the same theme, that the operating model is now where the alpha is. You can read the through-line across McKinsey’s research and BCG’s private equity practice: the funds that win are the ones treating commercial infrastructure as a controllable input, not a soft capability.
The first hundred days set the ceiling
What gets built in the first quarter of ownership determines what the rest of the hold looks like. If the data model is defined badly in month one, every downstream metric inherits the error, and by the time it surfaces in a board pack it is a credibility problem. I lay this out in detail in the 100-day go-to-market plan for a newly acquired B2B business, and the RevOps portion of it is deliberately narrow.
In the first hundred days I want three things and not a fourth. One, a single source of truth for the commercial pipeline that the CFO trusts. Two, a defensible baseline for the four numbers above. Three, one intervention shipped against the lever the thesis needs most. Anything beyond that is scope that will slow integration, and in an add-on heavy strategy, integration speed is itself a value driver. PitchBook’s data on deal activity, which you can track through PitchBook’s research, has shown how add-on-heavy the mid-market has become, and every add-on multiplies the cost of a messy commercial data model.
Where RevOps quietly protects the exit
The exit case is the part most portfolio operators underweight. A buyer’s diligence team will test the durability of the revenue, and a company that can produce clean, segmented, defensible commercial data walks into that process from a position of strength. A company that cannot is negotiating with its own uncertainty.
This connects directly to how earnings get presented. When you look at adjusted EBITDA and the art of add-backs, the credibility of a normalization argument depends on the quality of the underlying commercial data. An add-back tied to a discontinued product line lands very differently when RevOps can show the clean revenue split versus when it is a management assertion.The AICPA and CIMA guidance on financial reporting quality, is a useful reminder that at exit, defensibility beats optimism.
The failure modes I see most often
Three patterns account for most of the RevOps spend that never shows up in the model.
Tooling mistaken for transformation
A new CRM instance is not a strategy. I have seen six-figure implementations that changed which screen the reps ignored. The tool question is downstream of the process question, and the process question is downstream of the thesis question.
Dashboards nobody makes a decision from
If a report does not change a decision, it is cost. The test is simple: name the decision this dashboard informs and who makes it. If the answer is vague, kill the report. This ties to the discipline I describe in portfolio company operating reviews and the commercial KPIs that matter. An operating review is where good RevOps proves it changed behavior, not just visibility.
Building for an ideal company that does not exist yet
The most common miss in private equity GTM value creation pitfalls is designing the RevOps system for the company the deck imagines rather than the one you bought. The clean architecture assumes clean data, disciplined reps, and stable products. You have none of those on day one. Build for the messy reality and improve from there.
How I would brief the function on day one
If I owned the mandate, I would keep the charter to a single sentence: RevOps exists to make the commercial engine measurable and to move the one number the thesis depends on. Everything the function does gets justified against that sentence. Reporting that does not feed a decision, tooling that does not change a behavior, and projects that do not touch one of the four levers get cut.
I would also insist that the function report both up and across. Up to the CFO for forecast integrity, because a forecast the CFO will not defend is worthless, and across to the sales leadership for adoption, because a system the floor rejects is a sunk cost. The Harvard Law School Forum on Corporate Governance has plenty on why governance clarity and clean reporting lines matter more as leverage rises, and RevOps sits right at that seam. This is also the mindset behind future-proofing organizations for 2026: build the measurement discipline before you need it in a diligence room.
The decision, stated plainly
A deal partner or operating partner does not need to become a RevOps expert. They need to make one judgment well. Fund the version of this function that names a financial lever, sets a baseline, ships one real intervention, and reports a number that the CFO will defend to the board. Decline the version that leads with a stack, promises everything at once, and measures itself in activity.
The distinction is the same one that runs through everything I write about value creation. Activity is not outcome, advice without P&L accountability is decoration, and the only RevOps worth buying is the RevOps that changes an input in the model you underwrote at entry and can defend at exit.
If you are weighing a RevOps investment across a portfolio company or a platform, and you want a read from someone who has built these functions inside operating businesses rather than sold them from a deck, start with a business advisory conversation. If you want the delivery side, DevriX runs the demand and revenue infrastructure work directly through our services team. Either way, bring the four numbers. That is where the decision actually gets made.
